
Sign up to save your podcasts
Or
On this episode of Translating Proteomics, co-hosts Parag Mallick and Andreas Huhmer of Nautilus Biotechnology discuss how clinical researchers can leverage proteomics for drug development. Some of the themes covered in this episode include:
· Proteomics and pre-clinical models
· How proteomics can drive patient selection
· Choosing the right end points in clinical trials
Chapters
00:00 – 01:06 – Introduction
01:06 – 06:51 – Proteomics in pre-clinical studies
06:51 – 11:40 – The importance of choosing the right model for preclinical work
11:40 – 17:10 – How proteomics is used in Phase I/II clinical trials
17:10 – 19:29 – Proteomics tools in patient selection
19:29 – 24:33 – Useful information that we get from proteomics that we can’t get from genomics or transcriptomics
24:33 – 28:14 – Proteomics in Phase III clinical trials and picking the best indications of drug efficacy
28:14 – 29:19 - Understanding why clinical trials fail
29:19 – End - Outro
Resources
5
66 ratings
On this episode of Translating Proteomics, co-hosts Parag Mallick and Andreas Huhmer of Nautilus Biotechnology discuss how clinical researchers can leverage proteomics for drug development. Some of the themes covered in this episode include:
· Proteomics and pre-clinical models
· How proteomics can drive patient selection
· Choosing the right end points in clinical trials
Chapters
00:00 – 01:06 – Introduction
01:06 – 06:51 – Proteomics in pre-clinical studies
06:51 – 11:40 – The importance of choosing the right model for preclinical work
11:40 – 17:10 – How proteomics is used in Phase I/II clinical trials
17:10 – 19:29 – Proteomics tools in patient selection
19:29 – 24:33 – Useful information that we get from proteomics that we can’t get from genomics or transcriptomics
24:33 – 28:14 – Proteomics in Phase III clinical trials and picking the best indications of drug efficacy
28:14 – 29:19 - Understanding why clinical trials fail
29:19 – End - Outro
Resources
112,758 Listeners
12 Listeners